Showing 6,861 - 6,880 results of 18,343 for search 'significantly ((larger decrease) OR (((((a decrease) OR (mean decrease))) OR (nn decrease))))', query time: 0.66s Refine Results
  1. 6861
  2. 6862
  3. 6863
  4. 6864

    Image 1_Yacon root is a functional food beneficial for human health: a meta-analysis of clinical trials.pdf by Ling-Hui Pan (9341084)

    Published 2025
    “…The pooled results showed that YR significantly reduced BMI [SMD = −0.81, 95%CI (−1.54, −0.08)], decreased stool pH [SMD = −1.12, 95%CI (−1.61, −0.62)], softened stools [SMD = 0.94, 95%CI (0.08, 1.80)], facilitated defecation [SMD = 4.03, 95% CI (0.54, 7.52)], improved fiber consumption patterns [SMD = 0.58, 95%CI (0.18, −0.99)]. …”
  5. 6865

    Presentation 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  6. 6866

    Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  7. 6867

    Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  8. 6868

    Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  9. 6869

    Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi... by Gyeong Ho Baek (21382907)

    Published 2025
    “…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …”
  10. 6870
  11. 6871
  12. 6872
  13. 6873

    Table 1_Bifidobacterium compound preparations as a supplementary treatment for severe ischemic stroke: a systematic review and meta-analysis.docx by Shenghua Lu (20762612)

    Published 2025
    “…Regarding immune function, the BCP combination group significantly increased IgA (MD = 0.50, 95% CI 0.36 to 0.63, p < 0.00001) and IgG (MD = 3.00, 95% CI 2.03 to 3.97, p < 0.00001). …”
  14. 6874
  15. 6875

    Table 1_Age-related lung structure changes by quantitative assessment: a cross-sectional study in a Chinese male cohort.docx by Meijuan Shi (16999551)

    Published 2025
    “…</p>Conclusion<p>Lung aging is not a linear process, and the lung structural alterations in the upper and lower lobes exhibit significant heterogeneity.…”
  16. 6876
  17. 6877

    Kaplan-Meier plot. by Nand Lal Banstola (10510379)

    Published 2024
    “…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
  18. 6878

    Characteristics of the study sample. by Nand Lal Banstola (10510379)

    Published 2024
    “…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
  19. 6879

    Multivariate associations with incident leprosy. by Nand Lal Banstola (10510379)

    Published 2024
    “…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”
  20. 6880

    Univariate associations with incident leprosy. by Nand Lal Banstola (10510379)

    Published 2024
    “…</p><p>Findings</p><p>All four districts showed a decrease in case notification rates since 2015, with the steepest decline in the intervention districts. …”